definiens: shall mean ( a ) any Anti bodies * * * * * Invented and synthesized by [COMPANY] during the Capture Period or Invented and synthesiz ed by a Third Party during the Capture Period and Controlled by [COMPANY], together with all Antibodies w ithin the same Family of Antibodies as any such Ant ibodies and ( b ) any human pharmaceutical formulation contai ning or comprising such an Antibody described in ( a ), either alone or in combination with other active or inactive ingredients, components or materials ( whi ch such ingredients, components and materials are not IgE i nhibiting Antibodies ) in the same formulation as su ch Antibody ; provided, however, that Potential Product s shall in any event exclude all Anti - IgE Antibodie s and Anti - IgE Products ( each as defined in the TCA ) and any Abandoned Products . * * * * * 1.36 shall have the mean ing given thereto in Section 2.1